Last Updated: September 24, 2026

Patent: 9,815,886

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,815,886

Title:	Compositions and methods for the treatment of immunodeficiency
Abstract:	The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
Inventor(s):	Grossman; Adam S. (Saddle River, NJ), Mond; James (Silver Spring, MD), Grossman; Jerrold B. (Saddle River, NJ), Goldstein; Dov A. (New York, NY)
Assignee:	ADMA BIOLOGICS, INC. (Ramsey, NJ)
Application Number:	14/592,727
Patent Claims:	see list of patent claims

Details for Patent 9,815,886

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Adma Biologics, Inc.	NABI-HB	hepatitis b immune globulin (human)	Injection	103945	23-Oct-01	⤷ Start Trial	2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	21-May-04	⤷ Start Trial	2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	26-Mar-07	⤷ Start Trial	2035-01-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	11-Jul-14	⤷ Start Trial	2035-01-08
Adma Biologics, Inc.	BIVIGAM	immune globulin intravenous (human)	Injection	125389	19-Dec-12	⤷ Start Trial	2035-01-08
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	13-Nov-15	⤷ Start Trial	2035-01-08
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	25-Oct-16	⤷ Start Trial	2035-01-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,815,886

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2015246157	⤷ Start Trial
Australia	2021202598	⤷ Start Trial
Brazil	102015027387	⤷ Start Trial
Canada	2910491	⤷ Start Trial
European Patent Office	3026059	⤷ Start Trial
European Patent Office	4233903	⤷ Start Trial
Hong Kong	1225397	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.